BMS 193884

Drug Profile

BMS 193884

Latest Information Update: 16 Oct 2000

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Heart failure therapies
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Heart failure

Most Recent Events

  • 16 Oct 2000 A clinical study has been added to the Heart Failure pharmacodynamics section
  • 16 Oct 2000 Discontinued-II for Heart failure in USA (PO)
  • 03 May 2000 Phase-II clinical trials for Heart failure in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top